- Home
- CUE vs ZURA Comparison
CUE vs ZURA Comparison
Compare CUE & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- ZURA
- Stock Information
- Founded
- CUE 2014
- ZURA 2022
- Country
- CUE United States
- ZURA United States
- Employees
- CUE N/A
- ZURA N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CUE Health Care
- ZURA Health Care
- Exchange
- CUE Nasdaq
- ZURA Nasdaq
- Market Cap
- CUE 94.4M
- ZURA 101.2M
- IPO Year
- CUE 2018
- ZURA N/A
- Fundamental
- Price
- CUE $1.32
- ZURA $1.40
- Analyst Decision
- CUE Strong Buy
- ZURA Buy
- Analyst Count
- CUE 5
- ZURA 6
- Target Price
- CUE $5.00
- ZURA $15.80
- AVG Volume (30 Days)
- CUE 195.8K
- ZURA 449.4K
- Earning Date
- CUE 03-10-2025
- ZURA 03-12-2025
- Dividend Yield
- CUE N/A
- ZURA N/A
- EPS Growth
- CUE N/A
- ZURA N/A
- EPS
- CUE N/A
- ZURA N/A
- Revenue
- CUE $9,532,000.00
- ZURA N/A
- Revenue This Year
- CUE $73.11
- ZURA N/A
- Revenue Next Year
- CUE $11.02
- ZURA N/A
- P/E Ratio
- CUE N/A
- ZURA N/A
- Revenue Growth
- CUE 149.53
- ZURA N/A
- 52 Week Low
- CUE $0.45
- ZURA $1.35
- 52 Week High
- CUE $2.37
- ZURA $6.35
- Technical
- Relative Strength Index (RSI)
- CUE 48.32
- ZURA 32.26
- Support Level
- CUE $1.22
- ZURA $1.39
- Resistance Level
- CUE $1.54
- ZURA $1.63
- Average True Range (ATR)
- CUE 0.11
- ZURA 0.13
- MACD
- CUE -0.01
- ZURA 0.01
- Stochastic Oscillator
- CUE 35.29
- ZURA 9.62
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
About ZURA Zura Bio Limited
Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.